Friday, 20th November International Celiac Disease Symposium 2026

• Proteomics in Celiac Disease - Jorunn Stamnaes
• Spatial Omics in Celiac Disease - Michael FitzPatrick
• Immunopeptidomics in Celiac Disease - Anthony Purcell
• A distinct cellular ecosystem underlies tissue healing in celiac disease. - Veronica Locher
• Transcriptomic stratification of celiac disease reveals sex-, age-, and severity-dependent programs - Valentina Discepolo
• Rare but functional anti-tumour T-cell clones in the duodenal mucosa of type II refractory coeliac disease - Vanessa Mhanna and Anaïs Levescot

• Disease Overlap with Celiac Disease: NCGS, IBD, IBS - Peter Gibson
• Psychological Issues and Brain Fog in Celiac Disease - Simon Knowles
• Potential, Ultrashort and Asymptomatic Celiac Disease: Definitions, diagnosis, and approaches to management - Joseph Murray
• Understanding and managing ARFID - Rose-Marie Satherley
• X-ray crystal structures elucidate how autoantibodies enhance the activity of transglutaminase 3 in dermatitis herpetiformis - Julie Elisabeth Heggelund
• CHILDREN WITH DOWN SYNDROME DISPLAY A DISTINCT INTESTINAL MUCOSAL PHENOTYPE BEYOND CELIAC DISEASE - Roberta Rotondo
• From Single-Marker Testing to Multiparametric Serology in Dermatitis Herpetiformis - Patricia Wusterhausen

• Best Practice for Detecting and Diagnosing Celiac Disease - Claire Jansson-Knodell
• Common Management Challenges for Doctors' - Ritu Verma
• When Should a Dietitian Get Involved? - Cristian Costas
• Common Pediatric Issues in Celiac Disease Diagnosis and Management - Andrew Day
• Common Pediatric Dietary Issues in Celiac Disease - Sadie Nagle
• What is Best-Practice Follow-Up in Celiac Disease? - Mohamed Shiha

• Perspectives from the Food Allergy Field - Paul Turner
• The Gluten Reference Dose and GF Threshold from a Regulatory Perspective - Jasmine Lacis-Lee

• Ritlecitinib Attenuates Gluten-Induced Histologic and Immunologic Disease Activity in Celiac Disease: A Phase 2 Proof-of-Concept Study - Maureen M Leonard
• A Randomized, Double-Blind, Placebo-Controlled, Biological Proof-of-Concept Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biological Effects of DONQ52 in Celiac Disease Patients with Gluten Challenge (the DQB103CT Study) - Jason Tye-Din
• Evaluation of ANB033, an Investigational CD122 Antagonist Monoclonal Antibody, for the Treatment of Celiac Disease: A Novel Phase 1 Clinical Study Design - Juha Taavela
• TEV-53408, an Anti-IL-15, Significantly Attenuated Gluten-Induced Villous Change in Adults With Celiac Disease: Results From a Phase 2a Randomized, Placebo-Controlled Study - Juha Taavela
• Efficacy and Safety of FB102 in Adult Participants With Celiac Disease on a Gluten-Free Diet: A Phase 2, Randomized, Double-blind, Placebo-controlled Trial - Jason Tye-Din

Invited Speakers:

• Dr Claire Jansson-Knodell, Cleveland Clinic - "What the Latest Research Teaches Us About Managing Celiac Disease
• Dr Amelie Therrien, Celiac Center, Beth Israel Deaconess Medical Center - 'Celiac Beyond the Gut: Understanding and Managing Whole Body Symptoms'
• Mr Cristian Costas, Bradford Teaching Hospitals NHS Foundation Trust - 'Optimising the Gluten-Free Diet for Health and Enjoyment'
• Ms Vanessa Weisbrod, Celiac Disease Foundation - 'How Research on Cross-Contact, Social Life, and School Accommodations Can Protect You'
• Dr Maureen Leonard, Mass General Brigham/Harvard - 'Can We Prevent and Predict Celiac Disease in Children?'

Followed by Panel Discussion.

• What the Latest Research Teaches Us About Managing Celiac Disease - Claire Jansson-Knodell
• Celiac Beyond the Gut: Understanding and Managing Whole Body Symptoms - Amelie Therrien
• Optimising the Gluten-Free Diet for Health and Enjoyment - Cristian Costas
• How Research on Cross-Contact, Social Life, and School Accommodations Can Protect You - Vanessa Weisbrod
• Can We Prevent and Predict Celiac Disease in Children? - Maureen Leonard

• Coeliac disease autoimmunity and coeliac disease in the Environmental Determinants of Islet Autoimmunity pregnancy-to-childhood cohort study of Australian children at risk of type 1 diabetes - Rebecca Thomson
• Early-Life Screening for Celiac Disease in Genetically At-risk Children: the BABYSCREEN Study - Laura Kivelä
• Prevalence of Celiac disease in second generation south Indian migrants’ parallels that of native North Indians: A community-based epidemiological study - Samagra Agarwal
• Prenatal and early life vitamin A intake is not associated with the risk of celiac disease: The Norwegian Mother, Father, and Child cohort study - Elin HÅRD AF SEGERSTAD
• Does Early-Life Greenspace Shape Celiac Disease Risk? Evidence From a Swedish Birth Cohort - Nan Du
• Long-term gluten exposure without villous atrophy in adults with coeliac disease - Luca LE Elli
• The Recipe for Retention: Dietitian-Led Gluten-Free Diet Education as a Stronger Predictor of Pediatric Celiac Follow-Up Than Location, Insurance, or Comorbidities - Sadie Nagle

Invite only.

• Towards Global Harmonisation: Standardising Dietitian Assessments in Celiac Disease - Anne Lee
• Models of Follow-Up: Can a Dietitian-Led Celiac Clinic Work?' - Nick Trott
• Towards a Global Reference Dose for Gluten. What Might This Mean? - Penny Dellsperger
• Fact or Philosophy? An International Survey of How Dietitians Teach Cross-Contact in the Gluten-Free Diet - Sadie Nagle
• Virtual celiac dietitian: A language-agnostic conversational agent powered by augmented intelligence for personalised food recommendations in patients with celiac disease - Samagra Agarwal
• Gluten tolerance in non-adherent coeliac patients: A Systematic Review and Meta-analysis. - Luca LE Elli
• Quantifying Dietary Gluten Exposure from Shared Fryers: Implications for Nutritional Management and Health Outcomes in Celiac Disease   - Vanessa Weisbrod

• What are the Optimal Endpoints to Register a Celiac Drug? A Regulatory Perspective - Irena Lavine and Melissa Shapiro
• Validating PROs in Celiac Disease - Daniel Leffler
• Bridging Celiac Disease and Allergy: Lessons for Novel Therapies - Daniel Adelman
• Gluten Challenge and Immune Readouts in Celiac Disease - Knut Lundin

Closing Scientific and Clinical Highlights:

• Iris Jonkers, ISSCD President
• Fabiana Zingone, ISSCD President-Elect